Bladder cancer drug trial pulled before it even started
NCT ID NCT07313891
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after surgery. However, the trial was withdrawn before enrolling any participants, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NDV-01 (sustained-release gemcitabine-docetaxel)
- What this could lead to
- If it worked, this could offer a new treatment option to reduce bladder cancer recurrence after surgery.
- What could go wrong
- The trial was withdrawn before any participants enrolled, so no results are available. It is unclear if the drug is safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
- GPS for surgeons: navigation tech aims to simplify cancer lymph node removal
- Could a common vitamin restore immunotherapy power after antibiotics?
- Could less be more? bladder cancer trial tests stopping immunotherapy after tumors vanish
- New combo aims to wipe out rare bladder cancer before surgery
- Second look surgery may spot hidden bladder cancer